Antibody-drug conjugates combined with immunotherapy have redefined the standard of care for advanced bladder cancer, ...

Radiation therapy for gastrointestinal cancers is more precise and easier to tolerate due newer technologies and personalized ...

I stay in the cancer social media world because it helps me cope, even when friends disappear and I’m left wondering if ...

U.S. medical centers are seeking FDA authorization for the compassionate use — or expanded access — of Namodenoson for ...

Dr. Petros Grivas discusses the importance of tailoring treatment decisions in bladder cancer based on data from three ...

Patients with gastrointestinal cancer may benefit from multidisciplinary care and open communication with their care team, as ...

A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC.

Dr. Elizabeth K. Lee discusses the RAINFOL-01 clinical trial evaluating treatment with Rina-S in advanced ovarian cancer.

Bria-IMT plus check point inhibitors had a median overall survival which outperformed that of antibody-drug conjugates in HR+ ...

TLX101 therapy was efficacious in recurrent high-grade glioma, a type of brain cancer, according to preliminary results from ...

Treatment with bexmarilimab and Vidaza elicited high overall response rates in both frontline and relapsed/refractory ...

A phase 2a clinical trial of NEO100-01 is continuing to recruit patients with malignant gliomas, with full enrollment ...